Accéder au contenu
Merck

Chondrogenic capacity and alterations in hyaluronan synthesis of cultured human osteoarthritic chondrocytes.

Biochemical and biophysical research communications (2013-05-25)
Yohei Ono, Tadahiro Sakai, Hideki Hiraiwa, Takashi Hamada, Takaaki Omachi, Motoshige Nakashima, Shinya Ishizuka, Tetsuya Matsukawa, Warren Knudson, Cheryl B Knudson, Naoki Ishiguro
RÉSUMÉ

During osteoarthritis there is a disruption and loss of the extracellular matrix of joint cartilage, composed primarily of type II collagen, aggrecan and hyaluronan. In young patients, autologous chondrocyte implantation can be used to repair cartilage defects. However, for more elderly patients with osteoarthritis, such a repair approach is contraindicated because the procedure requires a large expansion of autologous chondrocytes in vitro leading a rapid, perhaps irreversible, loss of the chondrocyte phenotype. This study investigates whether osteoarthritic chondrocytes obtained from older patients can be expanded in vitro and moreover, induced to re-activate their chondrocyte phenotype. A decrease in chondrocyte phenotype markers, collagen II, aggrecan and SOX9 mRNA was observed with successive expansion of cells in monolayer culture. However, chondrogenic induction in three-dimensional pellet culture successfully rescued the expression of all three marker genes to native levels, even with 4th passage cells-cells representing an approximate 625-fold expansion in cell number. This data supports the use of osteoarthritic cells for autologous implantation repair. In addition, another set of gene products were explored as useful markers of the chondrocyte phenotype. Differentiated primary chondrocytes exhibited a common pattern of hyaluronan synthase isoforms that changed upon cell expansion in vitro and, reverted back to the original pattern following pellet culture. Moreover, the change in isoform pattern correlated with changes in the molecular size of synthesized hyaluronan.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hyaluronic acid sodium salt from Streptococcus equi, bacterial glycosaminoglycan polysaccharide
Sigma-Aldrich
Hyaluronic acid sodium salt from rooster comb, avian glycosaminoglycan polysaccharide
Sigma-Aldrich
Hyaluronic acid sodium salt from bovine vitreous humor
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 8,000-15,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 1,000,000-1,250,000
Sigma-Aldrich
Hyaluronic acid sodium salt from Streptococcus zooepidemicus, bacterial glycosaminoglycan polysaccharide
Sodium hyaluronate, BRP, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 300,000-500,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 30,000-50,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 1,500,000-1,750,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 2,000,000-2,400,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 1,200
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 50,000-70,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 10,000-30,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 70,000-120,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 2,000,000-2,200,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 15,000-30,000
Sigma-Aldrich
Acide hyaluronique sodium salt from Streptococcus equi, mol wt 120,000-350,000